From Blood Pressure Monitors to Pocket Ultrasound: Wireless Medical Devices in 132 FDA Submission Records, January 2025 to September 2026
The 510(k) Summary for OMRON Healthcare's upper-arm blood pressure monitor (K261929), cleared on September 10, 2026, lists one difference from its predicate: the addition of Bluetooth Low Energy (BLE). It says BLE is there to send stored readings to external applications and does not affect the measurement itself, that electromagnetic compatibility (EMC) testing was evaluated to include the BLE function, and that testing confirmed the data are not altered in transmission. Even on a home blood pressure monitor, adding a link to a smartphone is a change that has to be tested and explained.
Reading the public documents for 510(k)s, De Novos and original PMAs decided from January 2025 through September 2026, RA Craft Database identified 132 submission records for devices that communicate wirelessly and are worn, carried or used at home: 88 in 2025 and 44 from January to September 2026. These are submission records, not 132 distinct products: separate submissions for modifications of the same product are counted separately, and multiple models in one submission are counted once. Physiological monitoring, worn on the body or set up at home, is the largest group, followed by home therapy devices, home measurement devices, handheld imaging, and CGMs and insulin delivery.
How the 132 were found, and what is being counted
The pool is every 510(k), De Novo and original PMA with an FDA decision date between January 1, 2025 and September 30, 2026 for which RA Craft Database has extracted text from an FDA public document (510(k) Summary, Decision Summary, PMA SSED and the like): 5,440 records. PMA supplements are left out because they rarely have public documents.
A first pass picked out records whose text contains both a wireless term (Bluetooth, BLE, wireless, Wi-Fi, cellular, NFC and so on) and a portability or home-use term (portable, wearable, handheld, home use, patch and so on): 182 records. Each was then read in context, and these were removed: negations such as "no wireless capability," mentions limited to the name of a radio-frequency immunity standard, wireless footswitches and detectors on stationary surgical or X-ray equipment, stationary bedside monitors used only in hospitals, unrelated uses such as "cellular debris," records where the wireless feature in the comparison table belonged to the predicate, and records whose only wireless feature is power transfer from an external unit, with no data communication described.
Wireless communication was assessed at the system level, including accessories and companion apps described in the public documents. Besides descriptions of data being sent or received, a documented wireless function or wireless coexistence testing of the device counted as evidence. Devices that are not worn but are set up at home were included when their documents say they can be used there.
This approach cannot find records that RA Craft Database does not hold, records without public documents or extracted text, or wireless devices whose text did not match the search terms. Only 20 of the 53 De Novos in the period have extracted text, so De Novos are especially undercounted. The 132 are what public documents confirmed under these conditions, not a census of FDA records. The list of included records, and the reasons for records removed since the first version, are kept with the tally.
What is connecting wirelessly
| Field | 2025 | Jan–Sep 2026 | Typical devices |
|---|---|---|---|
| Physiological monitoring (wearable, portable or set up at home) | 30 | 15 | ECG patches, watch- and ring-type devices, sleep testing, EEG, respiration, fetal monitoring, a contactless bedside monitor |
| Therapy, stimulation and home treatment | 17 | 7 | Nerve and muscle stimulators, home tDCS, TTFields, portable oxygen concentrators, PAP |
| Portable and home measurement | 12 | 11 | Blood pressure monitors, pulse oximeters, thermometers, blood glucose meters |
| Portable imaging and diagnostics | 11 | 4 | Handheld ultrasound, portable X-ray, fundus camera |
| CGM and insulin delivery | 7 | 4 | CGMs, insulin pumps, apps paired with CGMs |
| Mobility | 7 | 2 | Power wheelchairs, wearable exoskeletons, a hip-protection airbag belt |
| Other | 4 | 1 | Wearable breast pumps, a hearing-aid fitting app |
Each record is placed in one field by its main function. Standalone blood glucose meters are in measurement; CGMs and insulin delivery devices form their own group.
Eighty of the 132 records describe a link to an app on a smartphone, tablet or other mobile device, or are themselves a mobile app. Records were not counted where the app runs on a PC, where the platform is not stated, or where "smartphone" appears only in clinical study eligibility criteria. Bluetooth, including BLE, is the most common radio, followed by Wi-Fi; a few use cellular networks. AI/ML was confirmed for nine records. Separately from AI, the most common wireless role was sending readings or device status to a phone or the cloud.
By quarter, 2025 ran 21, 24, 27 and 16; the first three quarters of 2026 ran 9, 13 and 22. Under the same search, January–September 2026 produced 44 records against 72 a year earlier. The number of records with extracted text was close, 2,307 in January–September 2025 and 2,352 in January–September 2026, but differences in document availability, extraction and level of detail by field also play a part, so the gap alone does not show a drop in FDA authorizations of wireless devices.
About one in four of the site's blood pressure monitor records has a confirmed wireless function
Blood pressure monitors stand out. RA Craft Database holds 56 product code DXN (noninvasive blood pressure measurement system) records for the period; of the 54 with extracted text, 15 have a confirmed wireless function for at least one covered model. A record without a confirmed wireless function is not necessarily a monitor without one.
There are six upper-arm blood pressure monitor submission records under the Joytech Healthcare name (K241431, K250548, K252685, K252501, K253425, K261394). Four say in their text that they include models with Bluetooth (BLE); the other two (K252685, K252501) list FCC rules for radio devices and wireless coexistence testing. Each submission covers several models, so the six are not a count of products. The ring-type Happy Health Blood Pressure Monitor (K254000) communicates with its mobile app over BLE and Wi-Fi, and the app moves the data to and from the cloud. And as with OMRON's K261929, adding BLE to an existing monitor is itself the subject of a 510(k).
Among blood glucose meters, Ascensia's CONTOUR NEXT GEN (K260545) has BLE built in to communicate with smartphones and tablets, and Transtek's TeleRPM Gen2 (K243060) connects over a cellular network through a 4G module.
Worn on the body or set beside the bed: ECG patches, watches, sleep tests
Physiological monitoring, at 45 records, is the largest group, and it includes devices set up at home as well as wearables. For ECG, InfoBionic's MoMe ARC (K250356) sends signals captured through a lead set or a patch to a gateway over a 2.4 GHz BLE link, alongside long-term recorders such as Peerbridge Health's COR MDx (K253529). On the wrist are the Masimo W1 (K243305), the seizure monitors EpiWatch (K243515) and Empatica's EpiMonitor (K250515), and Empatica's monitoring platform for Parkinson's disease (K260374). EpiWatch is an app on a wrist-worn device that transmits data over a cellular plan or Wi-Fi. Not everything is worn: Circadia's C300 (K261286) is a contactless monitor placed beside the bed that measures cardiorespiratory signals and streams them to the cloud over Wi-Fi, for use in care facilities and at home.
For sleep, Onera STS 2 (K243220), Compumedics' Somfit D (K252383) and Itamar's WatchPAT400 (K250460) send overnight data by Bluetooth to an app on the patient's mobile device. In pregnancy, there are GE's Novii+ Wireless Patch System (K254036) and Marani Health's M•care System (K253673), which acquires maternal and fetal vital signs for remote antenatal monitoring.
Wearable and home-use systems in original PMAs and De Novos
Among original PMAs and De Novos, devices used at home or on the body stand out.
Flow Neuroscience's Flow FL-100 (P230024, December 8, 2025) treats moderate to severe major depressive disorder with transcranial direct current stimulation at home. The headset communicates with a smartphone over BLE, and the app starts and pauses stimulation and tracks use.
Novocure's Optune Pax (P250034, February 11, 2026) is a portable device delivering tumor treating fields (TTFields) for locally advanced pancreatic cancer, used with chemotherapy. Patients can also send its log files to Novocure's servers over a cellular network using MyLink, an optional data transfer unit; it is that accessory, not the device itself, that transmits.
Element Science's Jewel (P230022, April 30, 2025) is a patch wearable cardioverter defibrillator. It contains a BLE microcontroller, and an optional iOS app mirrors the device's status, but the app cannot control or program the Jewel. Nyxoah's Genio System 2.1 (P240024, August 8, 2025) is a hypoglossal nerve stimulator for obstructive sleep apnea. Apart from transferring power wirelessly from an external unit on a skin patch to the implant, the external unit communicates with a smartphone app over BLE, which patients use to start and stop stimulation and adjust its strength within a preset range. Medtronic's Simplera Sync and Guardian 4 sensors (P250012, August 6, 2025) send CGM data over BLE to the company's automated insulin delivery system.
There are two De Novos. Active Protective Technologies' Tango Belt (DEN240021, April 9, 2025) is a belt worn by older adults at risk of hip fracture from falls; an airbag inflates when the wearer falls. Its Decision Summary lists wireless coexistence testing and cybersecurity documentation that covers the mobile app. Pulsenmore's Pulsenmore ES (DEN240074, October 31, 2025) is an ultrasound device that pregnant women at 14 to 38 weeks use at home with a smartphone, either guided by the app or directed remotely by a clinician; a physician interprets the images remotely.
Home therapy devices cleared through 510(k)
Among 510(k)s, the portable oxygen concentrators Caire FreeStyle Comfort (K250671) and BMC Medical PO1 (K260171) pair with smartphones or tablets over Bluetooth. Theranica's Nerivio (K250405), a wearable migraine stimulator, is controlled by a mobile app.
Handheld ultrasound goes probe-only wireless
In portable imaging, some ultrasound probes are themselves wireless. FUJIFILM Sonosite's iLOOK (K260595) uses a wireless transducer (L15-5) and has a wireless charger built into its transducer holder. Beijing Konted's Pocket Ultrasound System (K261081) is a series of wireless probes that connect directly to a smartphone over Wi-Fi. Handheld ultrasound from ASUS (K250791) and Edan (K251268), Oxos's MC2 portable X-ray (K252068) and Remidio's smartphone-based fundus camera (K252120) fall in the same group.
What CGMs and insulin pumps connect to
Dexcom accounts for six of the 11 CGM and insulin delivery records: the G7 15 Day system (K243214), later G7 changes, and the over-the-counter Stelo. The 2026 Stelo Summaries (K260935, K262472) describe a Direct to Watch feature that sends data over BLE straight to an Apple Watch. Among insulin pumps, Tandem's t:slim X2 (K250792) connects to a smartphone app over Bluetooth, and DEKA's twiist (K250930) works with an external wireless user interface and an iCGM.
What the public documents say about wireless testing and cybersecurity
For each of the 132 submission records, we checked whether any of its public documents mentions the items below. A record with several documents counts once, and one record can fall under several items, so the rows do not add up to 132. These are counts of public mentions, not rates of testing or compliance.
| Mention in public documents | Of 132 | 2025 (88) | Jan–Sep 2026 (44) |
|---|---|---|---|
| Cybersecurity | 64 | 39 | 25 |
| FDA's cybersecurity guidance by name | 44 | 24 | 20 |
| EMC (IEC 60601-1-2) | 83 | 55 | 28 |
| Home healthcare standard (IEC 60601-1-11) | 55 | 34 | 21 |
| Wireless coexistence | 40 | 28 | 12 |
| ANSI C63.27, the coexistence standard, by name | 32 | 21 | 11 |
| FCC rules or conformity | 21 | 11 | 10 |
| FDA's RF wireless guidance (2013) by name | 9 | 6 | 3 |
About half of the 132 records mention cybersecurity in their public documents. The share naming FDA's cybersecurity guidance was 24 of 88 (27%) for 2025 and 20 of 44 (45%) for January–September 2026. That is a share of public mentions; it says nothing by itself about rates of implementation or the effect of guidance revisions. FDA's "Cybersecurity in Medical Devices" guidance was revised on June 27, 2025, and that version was superseded by the February 3, 2026 edition, retitled with "Quality Management System Considerations." For wireless technology itself, FDA's final guidance is still "Radio Frequency Wireless Technology in Medical Devices" from August 2013.
Summaries vary by company, and a test that goes unnamed is not a test that was not done. De Novo Decision Summaries, written by FDA, are more detailed. Pulsenmore ES's Decision Summary says its cybersecurity documentation met the requirements of section 524B of the FD&C Act, including a threat model, a software bill of materials (SBOM), cyber risk management, labeling, cyber testing and postmarket vulnerability handling. It is the record of one product's review and does not apply in the same form to every wireless device, but it shows what can be explained in a public document.
Finding them in RA Craft Database
On Search, enter wireless or Bluetooth in the Keywords field and set the decision date from 2025 to list records with those words in the device description or indications. Enter DXN in the Product Code field for blood pressure monitors, or IYN for ultrasound systems including handhelds. Star (☆) the ones you want and line them up in the comparison table in My Workspace to see the indications and document links side by side.
Counts are taken from the RA Craft Database data loaded on October 7, 2026 (records with FDA decision dates through September 30, 2026) and were tallied by submission number on October 20, 2026. Wireless and portable status was judged from text RA Craft Database extracted from FDA public documents, first by keyword and then by reading each record. AI/ML status is what RA Craft Database could confirm in public documents. These are not official FDA statistics, and counts can change with each monthly data update.
RA Craft Database is an independent service and is not affiliated with or endorsed by the U.S. FDA. Articles are for general information on product development and regulatory research; they are not legal or regulatory advice for a specific device. Official FDA documents remain the authoritative source.
← All articles